Focused on developing chimeric antigen receptor T‑cell (CAR‑T) immunotherapies, the company specialized in engineering patients’ immune cells to target and destroy cancer. Its pipeline centered on treatments for leukemia and lymphoma, placing it among a wave of biotechnology firms advancing cell‑bas...
No congressional trades have been disclosed for Juno Therapeutics Inc Com (JUNO) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.